Open-label, single-arm, Phase IIIb study to demonstrate the efficacy and safety of a single dose of the new L-praziquantel orally disintegrating tablets in children age 2 to 6 years infected with Schistosoma haematobium (urogenital schistosomiasis)
100 项与 Merck Pty Ltd. (Australia) 相关的临床结果
0 项与 Merck Pty Ltd. (Australia) 相关的专利(医药)
100 项与 Merck Pty Ltd. (Australia) 相关的药物交易
100 项与 Merck Pty Ltd. (Australia) 相关的转化医学